Olema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Sam Slutsky reiterated a Buy rating on Olema Pharmaceuticals with a $24 price target. The recommendation is driven by the advancement of palazestrant for ER+ breast cancer and favorable Phase 3 positioning. Key catalysts include upcoming readouts from AstraZeneca’s SERENA-4 and Olema’s OPERA-01 trial by Q1 2027. Despite high burn and short interest, the two-year cash runway limits near-term financing risk, supporting the attractive risk-reward profile.
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Olema Pharmaceuticals today and set a price target of $24.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Sam Slutsky has given his Buy rating due to a combination of factors, including Olema’s continued advancement of palazestrant, its oral SERD/CERAN for ER+ breast cancer, and the favorable positioning of its Phase 3 program against competitors. He views the upcoming readouts from AstraZeneca’s SERENA-4 and Olema’s own OPERA-01 trial by Q1 2027 as key catalysts that could validate palazestrant’s differentiated profile, particularly if robust activity is demonstrated in the ESR1 wild-type population, where prior oral SERDs have struggled.
At the same time, he notes that Olema’s cash runway of roughly two years, despite a relatively high annual burn and notable short interest, appears sufficient to reach these major data events, which limits near-term financing risk while preserving upside to successful trial outcomes. Against this backdrop, Slutsky maintains his $24 price target, unchanged, reflecting a risk-reward he believes remains attractive given the potential commercial opportunity in ER+ breast cancer and the prospect that positive Phase 3 results could materially re-rate the shares.